Enhertu demonstrates transformative progression-free survival in HER2-positive metastatic breast cancer; data in lung and gastric cancers show strong efficacy across HER2-targetable tumours. Multiple trials reinforce the efficacy of Imfinzi combinations, including with novel immunotherapies, for lung cancer patients across settingsAstraZeneca will present new data across its diverse portfolio of cancer medicines at the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) Congress 2021. Read More